background
intraven
magnesium
sulfat
rescu
therapi
ad
bronchodil
system
steroid
therapi
moder
sever
asthma
uncommonli
administ
hypothes
nebul
magnesium
would
confer
benefit
without
undu
risk
design
method
patient
age
moder
sever
asthma
pram
sever
score
admit
infirmaryobserv
unit
care
random
doubleblind
admiss
receiv
mg
nebul
magnesium
normal
salin
placebo
receiv
intens
therapi
combin
nebul
albuterolipratropium
intraven
methylprednisolon
time
medic
readi
discharg
primari
outcom
sampl
size
chosen
detect
absolut
improv
improv
time
pram
sever
score
secondari
outcom
compar
overal
group
sever
asthma
subset
result
one
hundr
ninetyon
magnesium
sulfat
placebo
patient
met
criteria
analysi
group
similar
mean
baselin
pram
score
blind
activ
therapi
significantli
increas
blood
magnesium
level
hr
posttreat
complet
compar
placebo
vs
mmoll
p
import
advers
effect
acceler
failur
time
analysi
show
nonsignificantli
shorten
time
medic
readi
discharg
favor
magnesium
sulfat
group
ci
p
mean
time
readi
discharg
hr
sd
versuss
hr
sd
investig
placebo
group
respect
p
conclus
ad
nebul
magnesium
combin
nebul
bronchodil
system
steroid
therapi
fail
significantli
shorten
time
discharg
pediatr
patient
moder
sever
asthma
ad
magnesium
sulfat
treatment
inhal
combin
bronchodil
therapi
system
corticosteroid
moder
sever
pediatr
asthma
controversi
despit
repeat
intens
studi
decad
british
scottish
guidelin
recommend
magnesium
infus
adult
children
safeti
concern
retic
toward
provid
iv
access
sole
magnesium
therapi
lack
evid
benefit
leav
practition
face
pediatr
patient
gina
global
initi
asthma
recommend
magnesium
treatment
consid
children
intraven
magnesium
typic
reserv
rescu
treatment
sever
ill
patient
nebul
magnesium
therapi
seem
ineffect
adult
sever
asthma
recent
placebocontrol
multicent
trial
nebul
magnesium
therapi
children
sever
asthma
investig
consid
reduc
asthma
sever
score
one
hour
magnesium
treatment
statist
signific
clinic
insignific
differ
time
discharg
rate
hospit
admiss
continu
specul
asthmat
patient
nebul
magnesium
might
benefit
qatar
busiest
pediatr
emerg
centr
pec
experienc
acut
asthma
visit
total
visit
year
escal
infirmari
ie
shortstay
unit
admiss
children
fail
improv
substanti
inhal
bronchodil
oral
steroid
therapi
pec
asthma
visit
transfer
patient
fail
infirmari
pediatr
icu
pec
asthma
visit
often
requir
intub
nebul
magnesium
sulfat
inexpens
proven
therapeut
could
readili
generaliz
rich
poor
commun
alik
worldwid
prevent
potenti
downhil
clinic
cours
worrisom
pediatr
asthma
patient
present
sinc
moder
sever
asthma
patient
alreadi
prolong
length
stay
test
nebul
magnesium
ad
therapi
initi
rather
random
rescu
therapi
time
bronchodil
steroid
therapi
deem
fail
sought
enrol
children
present
moder
sever
asthma
blind
placebocontrol
trial
would
ensur
standard
therapi
optim
aerosol
technolog
confirm
system
magnesium
sulfat
deliveri
test
signific
differ
time
medic
readi
discharg
chose
largest
busiest
pec
alsadd
serv
approxim
visit
annual
infirmari
bed
prolong
stay
elig
subject
previous
known
asthma
moder
sever
exacerb
defin
pram
asthma
sever
score
asthma
defin
children
previou
physician
diagnosi
asthma
previou
histori
eczema
child
asthma
first
degre
famili
rel
increas
likelihood
true
asthma
children
previou
physician
diagnosi
asthma
suffici
patient
exclud
prematur
wk
gestat
critic
ill
present
requir
icu
admiss
intraven
bronchodil
therapi
noninvas
invas
ventil
etc
transfer
anoth
institut
histori
hypersensit
magnesium
sulfat
histori
neuromuscular
cardiac
renal
diseas
underli
structur
lung
diseas
receiv
system
steroid
theophyllin
ipratropium
within
prior
hr
pneumon
consolid
chest
radiograph
present
receipt
intraven
magnesium
sulfat
prior
random
prior
particip
studi
hemodynam
instabl
computergener
random
list
without
block
provid
pharmaci
result
prepar
identicalappear
seal
number
vial
contain
either
ml
sodium
chlorid
mg
magnesium
sulfat
ml
agre
nebul
magnesium
sulfat
dose
use
children
mg
given
studi
yearold
mg
given
recent
landmark
studi
yearold
vial
kept
clinic
area
identifi
random
number
block
stratif
studi
pharmacist
patient
interact
unawar
treatment
assign
patient
studi
personnel
blind
treatment
obtain
verbal
written
inform
consent
accompani
parent
patient
admit
infirmari
care
baselin
asthma
score
record
train
staff
chest
radiograph
intraven
line
insert
methylprednison
mgkg
iv
everi
hr
begun
dose
begun
nebul
ml
albuterol
mgml
mcg
ipratropium
bromid
ml
normal
salin
three
combin
bronchodil
dose
administ
hr
magnesium
sulfat
placebo
ad
first
hour
nebul
due
osmolar
consider
volum
limit
idehal
therefor
follow
next
hour
nebul
three
dose
studi
medic
activ
placebo
ml
albuterol
mgml
ad
ml
nebul
mosml
three
nebul
second
hour
afterward
patient
receiv
albuterol
nebul
hourli
hr
q
hr
readi
discharg
infirmari
care
addit
albuterol
nebul
three
backtoback
could
administ
decis
treat
physician
nebul
medic
given
tight
face
mask
pressur
lmin
except
studi
medic
given
aeroneb
pro
idehal
hold
chamber
studi
patient
nasal
swab
viral
mycoplasma
pcr
studi
oxygen
given
face
mask
need
keep
satur
vital
sign
record
baselin
hr
everi
hr
thereaft
asthma
sever
score
record
baselin
hr
unless
patient
discharg
abbrevi
icu
intens
care
unit
pram
pediatr
respiratori
assess
measur
pec
pediatr
emerg
centr
pcr
polymeras
chain
reaction
infirmari
earlier
time
patient
medic
readi
discharg
requir
feed
well
comfort
breath
satur
room
air
asthma
sever
score
record
discharg
patient
given
prednisolon
pill
syrup
complet
steroid
treatment
telephon
call
followup
studi
nurs
done
studi
patient
revisit
pec
need
repeat
infirmari
care
hospit
record
time
medic
readi
discharg
primari
outcom
measur
chose
rather
exampl
patient
requir
admiss
generaliz
across
hospit
varieti
criteria
requir
admiss
secondari
outcom
includ
asthma
sever
score
prespecifi
time
random
need
revisit
readmiss
infirmari
care
admiss
pediatr
icu
within
wk
discharg
ascertain
lower
airway
magnesium
deliveri
treat
group
blood
baselin
magnesium
level
obtain
iv
insert
hr
magnesium
sulfat
nebul
complet
hr
begun
observ
approxim
similar
patient
medic
readi
discharg
hr
enabl
detect
absolut
improv
investig
group
discharg
readi
power
twosid
alpha
estim
patient
per
group
requir
aim
enrol
per
group
account
dropout
exclus
power
would
provid
certainti
group
also
estim
sampl
size
power
plan
use
acceler
failur
time
model
compar
efficaci
treatment
group
statist
signific
p
acceler
hr
time
clinic
readi
discharg
would
favor
nebul
magnesium
sulfat
placebo
therapi
order
studi
efficaci
analyz
perprotocol
popul
exclud
patient
protocol
eg
inclus
procedur
violat
outcom
overal
patient
group
compar
patient
subset
meet
pram
criteria
sever
asthma
attack
also
collect
exploratori
comparison
categor
continu
variabl
express
percentag
mean
standard
deviat
sd
quantit
variabl
mean
two
treatment
group
analyz
unpair
wilcoxon
rank
sum
test
associ
qualit
categor
variabl
assess
chisquar
test
continu
correct
smaller
cell
frequenc
statist
analys
perform
use
spss
version
ibm
spss
statist
ibm
corpor
data
transfer
spss
packag
stata
se
chicago
il
acceler
time
failur
model
analysi
hamad
medic
corpor
human
studi
committe
approv
studi
inform
consent
form
may
august
februari
pediatr
moder
sever
asthma
patient
assess
studi
elig
random
inform
consent
lost
followup
conveni
sampl
sinc
although
pec
see
larg
number
asthmat
patient
recruit
limit
practic
reason
night
busi
time
key
personnel
otherwis
occupi
away
prior
receipt
outpati
steroid
larg
number
patient
one
hundr
ninetyon
nebul
magnesium
sulfat
placebo
nebul
patient
avail
analysi
patient
flow
includ
reason
exclus
analysi
present
figur
tabl
present
baselin
demograph
characterist
random
patient
clinic
import
differ
two
studi
group
mean
asthma
sever
score
mean
baselin
satur
third
patient
fever
nasopharyng
swab
posit
pcr
test
one
viral
pathogen
mean
durat
symptom
rang
fever
cough
baselin
serum
magnesium
level
normal
rang
similar
group
blood
magnesium
level
hr
complet
dose
nebul
magnesium
sulfat
hr
initi
nebul
magnesium
placebo
obtain
half
patient
group
sd
versu
sd
mmoll
p
student
test
magnesium
sulfat
n
level
placebo
n
level
group
respect
figur
frequenc
histogram
asthma
sever
score
baselin
hr
hr
show
similar
frequenc
sever
score
improv
magnesium
placebo
group
figur
show
kaplanmei
plot
medic
readi
discharg
infirmari
care
acceler
failur
time
analysi
show
nonsignificantli
rel
shorten
time
medic
readi
discharg
favor
magnesium
sulfat
group
ci
p
mean
time
readi
discharg
hr
sd
versu
hr
sd
investig
placebo
group
respect
absolut
improv
p
tabl
show
primari
secondari
outcom
overal
patient
group
tabl
subset
sever
asthma
preponder
data
analys
present
fail
show
signific
differ
suggest
differ
treatment
inhal
magnesium
sulfat
placebo
relev
outcom
truli
exist
must
quit
small
sever
asthma
subgroup
baselin
pram
score
mean
sd
sd
magnesium
sulfat
placebo
group
respect
clinic
statist
signific
differ
mean
median
data
shown
length
stay
need
oxygen
time
readi
discharg
tabl
hypotens
observ
vital
sign
observ
time
similar
treatment
group
one
patient
excess
cough
first
nebul
withdrawn
studi
parent
placebo
normal
salin
nebul
group
one
patient
magnesium
sulfat
group
chest
tight
third
nebul
facial
rash
without
oropharyng
involv
receiv
intraven
diphenhydramin
resolv
within
min
one
placebo
patient
requir
pediatr
icu
admiss
refractori
statu
asthmaticu
three
nebul
backtoback
dose
magnesium
sulfat
total
mg
three
nebul
dose
albuterol
ipratropium
intraven
methylprednisolon
appear
favor
affect
time
medic
readi
discharg
relev
clinic
paramet
compar
placebo
recipi
subset
patient
sever
asthma
present
behav
similarli
magnesium
sulfat
dose
use
prefer
nebul
system
lead
significantli
elev
mean
serum
magnesium
level
hr
nebul
complet
interpret
confirm
dose
deliveri
point
estim
mean
durat
prior
readi
discharg
hypothes
reflect
signific
benefit
hour
shorten
stay
improv
placebo
mean
hr
approxim
patient
per
group
would
requir
power
show
nonsignific
improv
determin
acceler
failur
time
analysi
true
somewhat
fewer
patient
would
requir
either
case
larg
number
patient
would
requir
hour
nebul
magnesium
sulfat
treatment
modest
clinic
gain
despit
theoret
attract
lack
advers
effect
though
exclud
possibl
benefici
effect
rare
patient
result
milit
make
nebul
magnesium
sulfat
avail
part
standard
armamentarium
pediatr
patient
present
commun
emerg
depart
moder
sever
asthma
although
review
sever
much
smaller
studi
adult
children
recommend
focus
nebul
magnesium
sulfat
evalu
sever
rather
moder
asthmat
conclus
drawn
accumul
small
patient
number
includ
adult
subject
dose
suboptim
deliveri
system
without
biochem
confirm
magnesium
sulfat
inde
deliv
studi
patient
two
recent
random
studi
seek
studi
sole
sever
asthmat
children
adult
found
effort
frustrat
includ
moder
asthmat
set
mani
sever
asthmat
alreadi
receiv
steroid
therapi
outpati
greatest
sever
often
becom
appar
treatment
rather
clearli
perceiv
present
reason
therapeut
popul
optim
clinic
trial
nebul
magnesium
sulfat
includ
children
present
moder
asthma
well
nebul
magnesium
could
studi
rescu
agent
sole
sever
asthmat
studi
intend
assess
efficaci
sole
sever
asthmat
underpow
interpret
result
requir
note
studi
limit
random
patient
administ
system
steroid
well
combin
bronchodil
treatment
intens
therapi
consist
exist
guidelin
prior
nebul
investig
therapi
possibl
dilut
proport
patient
remain
moder
sever
asthma
altern
design
studi
nebul
magnesium
sole
rescu
therapi
failur
bronchodil
steroid
therapi
unapp
uniform
gener
definit
failur
certainli
would
consum
consider
time
present
fail
goal
test
efficaci
safeti
proof
deliveri
therapi
could
ad
earli
moder
sever
asthmat
counterbalanc
possibl
concern
clinic
cours
studi
patient
whose
mean
infirmari
stay
durat
medic
readi
discharg
nonetheless
prolong
hr
despit
receipt
system
steroid
therapi
treatment
moder
sever
asthma
also
possibl
substanti
higher
nebul
magnesium
sulfat
dose
gave
three
dose
may
provid
demonstr
benefit
although
treat
group
persist
elev
magnesium
level
hr
initi
magnesium
nebul
obtain
pharmacokinet
measur
allow
comparison
intraven
magnesium
dose
howev
nebul
dose
mg
higher
mg
nebul
recent
trial
children
mg
test
adult
moreov
one
patient
abl
discharg
infirmari
care
without
icu
admiss
conclud
ad
nebul
magnesium
sulfat
combin
nebul
bronchodil
system
steroid
therapi
either
weakli
rare
effect
futil
benefit
pediatr
patient
moder
sever
asthma
